Advances Using Cord Blood in Stem Cell Transplants
Experts have long known that blood stem cells extracted from umbilical cords can be used to treat those lymphomas and leukemias via transplant. Unfortunately, there's always been one roadblock: the average umbilicus contains only enough stem cells to help the smallest patients, mainly children.
That's why the early results of a new study are so encouraging. Researchers at the Dana-Farber Cancer Institute in Boston say they have successfully treated adult blood cancer patients using stem cells extracted from two separate cords.
"The remarkable thing about it is that there are no apparent adverse consequences of using two cords, and the new blood cells seem to come in faster, with more rapid engraftment," explained Dr. Robert Soiffer, chief of hematologic malignancies at Dana-Farber. More Info
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
